Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced …
网页2024年9月12日 · There were 9 incident cases among 1,087 individuals in the Truvada group (incidence 0.93 per 100 person-years). Twice-yearly lenacapavir was 89% more effective than once-daily Truvada (incidence rate ratio 0.11, p=0.00245). In the trial, lenacapavir and Truvada were generally well-tolerated and no significant …
Twice-a-year injection reduced risk of HIV infection by 96%, drug …
网页2024年9月12日 · Another trial found that taking the long-acting injectable lenacapavir as pre-exposure prophylaxis can provide total protection against HIV acquisition in women, demonstrating 100% efficacy among...
An injectable HIV-prevention drug is highly effective - NBC News
网页2024年9月12日 · Thrilled over the news Thursday that lenacapavir was 89% more effective at preventing HIV than daily oral preventive medication among gay, bisexual and transgender people, plus previous news...
Twice-yearly shot proves successful at preventing HIV infection …
网页2024年7月24日 · The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and...
Long-acting injectable lenacapavir proves effective in HIV …
网页2024年7月26日 · WHO welcomes the news that long-acting injectable lenacapavir as pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV acquisition in women. This represents a significant breakthrough in HIV prevention. The full results of the PURPOSE 1 trial, presented at the 25th International AIDS Conference, demonstrate the safety and ...
Gilead Lenacapavir cut HIV infections by 96% in trial
网页2024年9月12日 · A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug. Gilead ’s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday ...
New HIV drug can only offer hope of ending AIDS if all have …
网页GENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention. The result “provides hope of accelerating efforts to end AIDS”, UNAIDS says, “but only if Gilead ensures that all people who need it can have access to this game-changing ...
NIH Statement on Preliminary Efficacy Results of Twice-Yearly ...
网页2024年6月26日 · The injectable antiretroviral drug lenacapavir was safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a Phase 3 clinical trial, according to top-line findings released by Gilead Sciences, Inc., the …
Gileads Twice Yearly Lenacapavir Demonstrated 100 Efficacy and ...
网页2024年6月20日 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women.
Gilead’s Investigational Lenacapavir Demonstrates Sustained …
网页2021年3月9日 · Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV infection. Lenacapavir's multi-stage mechanism of action profile is distinguishable from currently approved classes of antiviral agents and is designed to provide a new avenue for …
跳至内容